BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.02 USD | +12.98% |
|
+5.44% | -11.76% |
| May. 07 | Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
| May. 07 | Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on Beam Therapeutics Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.03% | 2 M€ | -25.75% | ||
| 4.10% | 0 M€ | 0.00% | - | |
| 4.00% | 1 M€ | 0.00% | - | |
| 0.79% | 1 M€ | -.--% | - | |
| 0.69% | 14 M€ | -4.28% | ||
| 0.46% | 115 M€ | +2.02% | - | |
| 0.27% | 0 M€ | 0.00% | - | |
| 0.27% | 1 M€ | +2.21% | - | |
| 0.23% | 2 M€ | -.--% | ||
| 0.21% | 0 M€ | 0.00% | - | |
| 0.08% | 7 M€ | -.--% | - | |
| 0.07% | 1,487 M€ | +7.21% | - | |
| 0.03% | 746 M€ | -.--% | - | |
| 0.03% | 9 M€ | -.--% | - | |
| 0.01% | 45 M€ | 0.00% | - | |
| 0.01% | 9 M€ | +9.07% | - | |
| 0.01% | 17 M€ | +4.26% | - | |
| 0.00% | 34 M€ | +3.39% | - |
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
24.02
USD
Average target price
48.38
USD
Spread / Average Target
+101.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.76% | 1.68B | |
| +26.37% | 44.96B | |
| -1.01% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +9.34% | 26.08B | |
| -21.69% | 19.03B | |
| +6.23% | 12.75B | |
| +26.99% | 12.06B | |
| -3.38% | 11.75B |
- Stock Market
- Equities
- BEAM Stock
- Funds and ETFs Beam Therapeutics Inc.